trial

Genetic Counselling in the Prevention of Mental Health Consequences of Cannabis Use

NCTId NCT03601026

as of 2026-07-01

Add to landscape Monitor this Ask about this

at a glance

— · Recruiting

Enrollment 120 (estimated)

Sponsored by Nova Scotia Health Authority

Primary completion 2026-09-01

Synthesized from structured facts only — each point cited above.

Design & status

Phase

—

Status

Recruiting

Enrollment

120 (estimated)

Study type

Interventional

Allocation

Randomized

Model

Parallel

Masking

Single

Start

2019-11-01

Primary completion

2026-09-01

Eligibility

ALL · 12 Years · 21 Years

Interventions & indications

Drugs

Genetic counselling

Indications

Bipolar Disorder Major Depressive Disorder Psychosis Depressive Disorder, Major Psychotic Disorders Schizophrenia Bipolar Disorder Schizophrenia Cannabis Use Mental Illness Mental Disorders

Investigators

Rudolf Uher, MD, PhDPrincipal Investigator

Sites

1 total

Halifax, Canada

Facts & assertions

4 sourced

Enrollment

120

Phase

Primary Completion Date

2026-09-01

Status

RECRUITING

relationships

The graph out of here

drug

Genetic counselling

drug

lead_sponsor

Nova Scotia Health Authority

company

indication

Bipolar Disorder

indication

Major Depressive Disorder

indication

Psychosis

indication

investigator

Rudolf Uher, MD, PhD

person